Building on our previous work demonstrating that GIPC1 is overexpressed in PDAC and associated with poor prognosis [10,11], the present study was designed to develop and evaluate a novel tumor-targeted liposomal delivery system (LGIPCsi) for RNA interference against GIPC1. Here, GIPC1 is linked to neoplasm.